Olympus Acknowledges FDA Import Alerts for Certain Devices Manufactured at Aizu Facility, Japan

TOKYO, June 27, 2025 – On June 24, 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) published import alerts for certain medical devices manufactured at the company's Aizu facility in Fukushima, Japan. This action prevents the import of the specified devices into the U.S. until further notice. The devices affected include certain bronchoscopes, laparoscopes, ureterorenoscopes, and automated endoscope reprocessors.

Olympus is committed to addressing the FDA's concerns promptly and ensuring that our products meet the highest quality standards. Our highest priority is providing our customers with safe and effective solutions for patient care.

For reference, the revenue generated by these devices in the U.S. accounted for approximately 1% of Olympus' consolidated revenue for the fiscal year ended March 2025. It is important to note that at this stage, and based on our initial evaluation, this action does not impact the import of these devices into any other countries globally.

Please refer to the FDA alert for full scope information: Import Alerts for Certain Olympus Medical Devices Manufactured in Japan - Letter to Health Care Providers | FDA

About Olympus

At Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit olympus-global.com.

[Inquiries regarding this release]
Company: Olympus Corporation (Code: 7733, Prime, Tokyo Stock Exchange)
Contact: Takaaki Sakurai, Vice President, Investor Relations (TEL: +81-42-642-2111)